Pediatric Clinical Trials Market (By Phase: Phase II, IV; By Study Design: Treatment, Observational Studies; By Therapeutic Areas: Mental Health Disorders, Oncology)- Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Therapeutic Areas Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Pediatric Clinical Trials Market 

5.1. COVID-19 Landscape: Pediatric Clinical Trials Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Pediatric Clinical Trials Market, By Phase

8.1. Pediatric Clinical Trials Market, by Phase Type, 2022-2030

8.1.1. Phase I

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Phase II

8.1.2.1. Market Revenue and Forecast (2017-2030)

8.1.3. Phase III

8.1.3.1. Market Revenue and Forecast (2017-2030)

8.1.4. Phase IV

8.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Pediatric Clinical Trials Market, By Study Design

9.1. Pediatric Clinical Trials Market, by Study Design, 2022-2030

9.1.1. Treatment Studies

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. Observational Studies

9.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Pediatric Clinical Trials Market, By Therapeutic Areas 

10.1. Pediatric Clinical Trials Market, by Therapeutic Areas, 2022-2030

10.1.1. Infectious Diseases

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Oncology

10.1.2.1. Market Revenue and Forecast (2017-2030)

10.1.3. Autoimmune/Inflammatory Diseases

10.1.3.1. Market Revenue and Forecast (2017-2030)

10.1.4. Respiratory Disorders

10.1.4.1. Market Revenue and Forecast (2017-2030)

10.1.5. Mental Health Disorders

10.1.5.1. Market Revenue and Forecast (2017-2030)

10.1.6. Others

10.1.6.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Pediatric Clinical Trials Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Phase (2017-2030)

11.1.2. Market Revenue and Forecast, by Study Design (2017-2030)

11.1.3. Market Revenue and Forecast, by Therapeutic Areas (2017-2030)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Phase (2017-2030)

11.1.4.2. Market Revenue and Forecast, by Study Design (2017-2030)

11.1.4.3. Market Revenue and Forecast, by Therapeutic Areas (2017-2030)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Phase (2017-2030)

11.1.5.2. Market Revenue and Forecast, by Study Design (2017-2030)

11.1.5.3. Market Revenue and Forecast, by Therapeutic Areas (2017-2030)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Phase (2017-2030)

11.2.2. Market Revenue and Forecast, by Study Design (2017-2030)

11.2.3. Market Revenue and Forecast, by Therapeutic Areas (2017-2030)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Phase (2017-2030)

11.2.4.2. Market Revenue and Forecast, by Study Design (2017-2030)

11.2.4.3. Market Revenue and Forecast, by Therapeutic Areas (2017-2030)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Phase (2017-2030)

11.2.5.2. Market Revenue and Forecast, by Study Design (2017-2030)

11.2.5.3. Market Revenue and Forecast, by Therapeutic Areas (2017-2030)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Phase (2017-2030)

11.2.6.2. Market Revenue and Forecast, by Study Design (2017-2030)

11.2.6.3. Market Revenue and Forecast, by Therapeutic Areas (2017-2030)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Phase (2017-2030)

11.2.7.2. Market Revenue and Forecast, by Study Design (2017-2030)

11.2.7.3. Market Revenue and Forecast, by Therapeutic Areas (2017-2030)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Phase (2017-2030)

11.3.2. Market Revenue and Forecast, by Study Design (2017-2030)

11.3.3. Market Revenue and Forecast, by Therapeutic Areas (2017-2030)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Phase (2017-2030)

11.3.4.2. Market Revenue and Forecast, by Study Design (2017-2030)

11.3.4.3. Market Revenue and Forecast, by Therapeutic Areas (2017-2030)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Phase (2017-2030)

11.3.5.2. Market Revenue and Forecast, by Study Design (2017-2030)

11.3.5.3. Market Revenue and Forecast, by Therapeutic Areas (2017-2030)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Phase (2017-2030)

11.3.6.2. Market Revenue and Forecast, by Study Design (2017-2030)

11.3.6.3. Market Revenue and Forecast, by Therapeutic Areas (2017-2030)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Phase (2017-2030)

11.3.7.2. Market Revenue and Forecast, by Study Design (2017-2030)

11.3.7.3. Market Revenue and Forecast, by Therapeutic Areas (2017-2030)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Phase (2017-2030)

11.4.2. Market Revenue and Forecast, by Study Design (2017-2030)

11.4.3. Market Revenue and Forecast, by Therapeutic Areas (2017-2030)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Phase (2017-2030)

11.4.4.2. Market Revenue and Forecast, by Study Design (2017-2030)

11.4.4.3. Market Revenue and Forecast, by Therapeutic Areas (2017-2030)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Phase (2017-2030)

11.4.5.2. Market Revenue and Forecast, by Study Design (2017-2030)

11.4.5.3. Market Revenue and Forecast, by Therapeutic Areas (2017-2030)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Phase (2017-2030)

11.4.6.2. Market Revenue and Forecast, by Study Design (2017-2030)

11.4.6.3. Market Revenue and Forecast, by Therapeutic Areas (2017-2030)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Phase (2017-2030)

11.4.7.2. Market Revenue and Forecast, by Study Design (2017-2030)

11.4.7.3. Market Revenue and Forecast, by Therapeutic Areas (2017-2030)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Phase (2017-2030)

11.5.2. Market Revenue and Forecast, by Study Design (2017-2030)

11.5.3. Market Revenue and Forecast, by Therapeutic Areas (2017-2030)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Phase (2017-2030)

11.5.4.2. Market Revenue and Forecast, by Study Design (2017-2030)

11.5.4.3. Market Revenue and Forecast, by Therapeutic Areas (2017-2030)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Phase (2017-2030)

11.5.5.2. Market Revenue and Forecast, by Study Design (2017-2030)

11.5.5.3. Market Revenue and Forecast, by Therapeutic Areas (2017-2030)

Chapter 12. Company Profiles

12.1. ICON plc

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Syneos Health

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Medpace, Inc.

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. PPD Inc.

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Premier Research

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. LabCorp Drug Development

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. QPS Holdings.

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Pfizer Inc.

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. The Emmes Company, LLC

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. IQVIA Inc.

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms